|Videos|March 20, 2017

What Do We Know About Zika Virus in Indigenous Populations?

David A. Schwartz, MD, MS Hyg, FCAP, clinical professor of pathology at Medical College of Georgia, Augusta University, discusses Zika virus in indigenous populations.

David A. Schwartz, MD, MS Hyg, FCAP, clinical professor of pathology at Medical College of Georgia, Augusta University, discusses Zika virus in indigenous populations.

Interview Transcript (slightly modified for readability)

“We know very little about Zika virus in indigenous populations. Of course indigenous populations in the setting of the Zika outbreak would include native populations and populations of non-Western origin in the effected countries, such as Brazil, Colombia, Mexico, and Central America, and recently in Africa.

There’s just very little known about [Zika infection in] these populations at all, unfortunately.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.